
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Because H5N1 influenza A viruses have the potential to cause a worldwide pandemic with mortality rates as high as 60 percent, the development of broadly protective vaccines is imperative, according to a seminar published in the April 26 issue of The Lancet.






